A small proof-of-principle trial suggests MDMA-assisted therapy may be feasible and effective for depression, but open-label design and a highly pre-treated sample urge caution.
[read the full story...]
Despite psychedelics’ roots in Indigenous and minoritised communities, clinical trials overwhelmingly centre White participants. This review highlights the consequences and asks how research can change.
[read the full story...]
Experts from across clinical trials, psychotherapy and regulation have been reflecting on the big challenges facing the field of psychedelics and mental health, following a late 2024 webinar hosted by IAMHRF. This new commentary explores where psychedelic mental health treatments might be heading and what needs to happen next.
[read the full story...]
